Kenvue Inc. $KVUE Stake Boosted by Private Trust Co. NA

Private Trust Co. NA increased its stake in Kenvue Inc. (NYSE:KVUE) by 75.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,977 shares of the company’s stock after purchasing an additional 5,158 shares during the quarter. Private Trust Co. NA’s holdings in Kenvue were worth $251,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. increased its stake in Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after purchasing an additional 4,034 shares in the last quarter. Renaissance Capital LLC grew its stake in Kenvue by 8.3% during the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Kenvue by 80.7% during the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after acquiring an additional 16,164 shares in the last quarter. Arlington Partners LLC purchased a new position in Kenvue during the 2nd quarter valued at about $2,110,000. Finally, Cornell Pochily Investment Advisors Inc. grew its stake in Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after acquiring an additional 19,609 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE KVUE opened at $14.96 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $28.71 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The company has a 50 day moving average price of $18.42 and a two-hundred day moving average price of $20.97. Kenvue Inc. has a 12-month low of $14.05 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company’s revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 5.5%. Kenvue’s dividend payout ratio is presently 112.16%.

Analyst Ratings Changes

Several research firms have weighed in on KVUE. JPMorgan Chase & Co. lowered their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. The Goldman Sachs Group lowered their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, October 2nd. Royal Bank Of Canada lowered their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. UBS Group lowered their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Finally, Zacks Research raised Kenvue to a “strong sell” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.